Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
ALTEOGEN will issue and list 40,820 additional common shares following the exercise of stock options by executives and employees. The listing date is set for September 30, 2025.
📊 [Key Disclosure Details & Major Figures Summary]
- Company Name: ALTEOGEN Inc. (Ticker: A196170)
- Type & Number of Additional Shares: Common Stock 40,820 shares
- Par Value per Share: KRW 500
- Total Issued Shares After Listing: Common Stock 53,505,788 shares (Dividend record date: January 01, 2025)
- Listing Date: September 30, 2025
- Issuance Breakdown (Stock Option Exercises):
- 114th Tranche (Issued Sep 17, 2025): 38,000 Common shares / Exercise price KRW 63,889
- 115th Tranche (Issued Sep 17, 2025): 2,400 Common shares / Exercise price KRW 62,858
- 116th Tranche (Issued Sep 17, 2025): 420 Common shares / Exercise price KRW 47,417
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verification of Additional Share Listing Schedule and Total Listed Share Count
This disclosure formally reports the additional listing of new common shares resulting from stock option exercises. Confirming that the 40,820 new common shares are listed on the scheduled date (September 30, 2025) and accurately reflected in the total listed share count (53,505,788 shares) is essential because it allows investors to verify the completion of the new share listing process. Detailed updates can be cross-checked in subsequent periodic reports (Quarterly, Half-Yearly, and Annual Reports) and related disclosure filings.
📢 Disclaimer & Source Notice
Source: This content has been structured and newly created based on official filing data from the Financial Supervisory Service (DART).
Investment Risk Notice: This content is provided for informational and language reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
